by Madaline Spencer | Jun 29, 2026
Vlado Perkovic, MD, Professor of Medicine and Provost at the University of New South Wales Sydney, discusses results from the VISIONARY clinical trial testing Voyxact (sibeprenlimab) in patients with IgA nephropathy (IgAN). IgAN is due to the...
by Madaline Spencer | Jun 26, 2026
Eunice S. Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, discusses long-term results of ziftomenib in combination with venetoclax and azacitidine in patients with acute myeloid leukemia (AML). AML is a cancer that affects the...
by Madaline Spencer | Jun 25, 2026
A study published in The Lancet Hematology evaluated the efficacy and safety of deucrictibant for the on-demand treatment of hereditary angioedema (HAE) attacks. Hereditary angioedema (HAE) is a rare condition characterized by recurrent episodes of severe swelling of...
by Madaline Spencer | Jun 25, 2026
Saad Usmani, MD, Hematologist-Oncologist at Memorial Sloan Kettering Cancer Center, discusses results from the CEPHEUS clinical trial of daratumumab combination therapy in patients with newly diagnosed multiple myeloma (MM). MM is a rare blood cancer...
by Madaline Spencer | Jun 24, 2026
A study published in Nature Medicine evaluated whole-exome sequencing data from the DECLARE-TIMI 58 clinical trial to determine whether sodium–glucose cotransporter 2 (SGLT2) inhibition is beneficial to patients with rare variants in cardiomyopathy-associated genes....
